Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type, By Treatment (Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025

Published: Mar, 2018 | Pages: 100 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The global rare hemophilia factors market size is anticipated to reach USD 336.3 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.1% during the forecast period. Several factor concentrates gaining marketing approvals from regulatory bodies such as the U.S. FDA are expected to provide a significant push to the market. In addition, growing adoption of prophylaxis treatment by patients is expected to boost the growth of the market in coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are escalating the growth of the market. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs and 554 drugs were approved by the U.S. FDA. Several key market players in the market are focusing on R&D to launch new products and solutions for the treatment of rare hemophilia factor disorders. For instance, in October 2015, FDA approved Coagadex for treatment of hereditary factor X deficiency. Introduction of new factor concentrates is likely to bolster market growth over the forecast period.

Further key findings from the study suggest:

• Based on type, factor VII accounted for the largest share in 2016, owing to higher prevalence of this deficiency

• Factor concentrates is anticipated to be the most promising segment, registering a CAGR of 5.7% over the forecast period. This type of treatment is considered to be the safest and most effective treatment for rare hemophilia factor disorders

• Fresh frozen plasma is estimated to command just over 53.0% of the market value by 2025

• Asia Pacific rare hemophilia factors market is expected to exhibit the highest CAGR of over 5.5% during the same period. The growth of the region can be attributed to wide base of population and high number of consanguineous marriage

• Some of the key players in the market are Novo Nordisk; Biogen; Bayer healthcare; Pfizer, Inc.; Baxalta; CSL Behring; and Bio Products Laboratory Ltd.

 Table of Contents

Chapter 1 Executive Summary
Chapter 2 Research Methodology
                 2.1 Information Procurement
                 2.2 Data Analysis
                      2.2.1 Region Wise Market: Base Estimates
                      2.2.2 Global Market: CAGR Calculation
                 2.3 List of Secondary Sources (partial list)
                 2.4 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
                 3.1 Market Segmentation
                 3.2 Market Size and Growth Prospects
                      3.2.1 Market driver analysis
                           3.2.1.1 Recent approvals of factor concentrates by regulatory bodies
                           3.2.1.2 Favorable government initiatives and mandates
                           3.2.1.3 Rising adoption of prophylaxis treatment
                      3.2.2 Market restraint analysis
                           3.2.2.1 High cost of treatment
                           3.2.2.2 Low adoption rate of new products launched
                 3.3 Penetration & Growth Prospect Mapping
                 3.4 Rare hemophilia factors market- SWOT analysis, by factor (Political & Legal, Economic and Technological)
                 3.5 Market SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
                      3.5.1 Political & legal factors
                           3.5.1.1 Strength
                           3.5.1.2 Weakness
                           3.5.1.3 Opportunity
                           3.5.1.4 Threat
                      3.5.2 Economic factors
                           3.5.2.1 Strength
                           3.5.2.2 Weakness
                           3.5.2.3 Opportunity
                           3.5.2.4 Threat
                      3.5.3 Social and environmental factors
                           3.5.3.1 Strength
                           3.5.3.2 Weakness
                           3.5.3.3 Opportunity
                           3.5.3.4 Threat
                 3.6 Industry Analysis - Porter's
                      3.6.1 Porter's Five Forces Analysis
                           3.6.1.1 Competitive rivalry
                           3.6.1.2 Bargaining power of suppliers
                           3.6.1.3 Bargaining power of buyers
                           3.6.1.4 Threat of new entrants
                           3.6.1.5 Threat of substitutes
Chapter 4 Rare Hemophilia Market: Type Estimates & Trend Analysis
                 4.1 Rare Hemophilia Factors Market: Type Movement Analysis
                 4.2 Factor I (Fibrinogen) Deficiency
                      4.2.1 Factor I market, 2014 - 2025 (USD Million)
                 4.3 Factor II (Prothrombin) Deficiency
                      4.3.1 Factor II market, 2014 - 2025 (USD Million)
                 4.4 Factor V (Labile Factor, Proaccelerin) Deficiency
                      4.4.1 Factor V market, 2014 - 2025 (USD Million)
                 4.5 Factor VII (Labile Factor or Proconvertin) Deficiency
                      4.5.1 Factor VII market, 2014 - 2025 (USD Million)
                 4.6 Factor X (Stuart-Prower Factor) Deficiency
                      4.6.1 Factor X market, 2014 - 2025 (USD Million)
                 4.7 Factor XI Deficiency (Hemophilia C, Plasma Thromboplastin Antecedent (PTA) Deficiency
                      4.7.1 Factor XI market, 2014 - 2025 (USD Million)
                 4.8 Factor XIII (Fibrin Stabilizing Factor) Deficiency
                      4.8.1 Factor XIII market, 2014 - 2025 (USD Million)
Chapter 5 Rare Hemophilia Market: Treatment Estimates & Trend Analysis
                 5.1 Rare hemophilia factors market: Treatment Movement Analysis
                 5.2 Factor Concentrate
                      5.2.1 Factor concentrate market, 2014 - 2025 (USD Million)
                 5.3 Fresh frozen plasma (FFP)
                      5.3.1 Fresh frozen plasma market, 2014 - 2025 (USD Million)
                 5.4 Cryoprecipitate
                      5.4.1 Cryoprecipitate market, 2014 - 2025 (USD Million)
                 5.5 Others
                      5.5.1 Others market, 2014 - 2025 (USD Million)
Chapter 6 Rare Hemophilia Market: Regional Estimates & Trend Analysis
                 6.1 Rare hemophilia Factors Market Share by Region, 2016 & 2025
                 6.2 North America
                      6.2.1 North America rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.3 U.S.
                      6.3.1 U.S. rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.4 Canada
                      6.4.1 Canada rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.5 Europe
                      6.5.1 Europe rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.6 U.K.
                      6.6.1 U.K. rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.7 Germany
                      6.7.1 Germany rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.8 Asia Pacific
                      6.8.1 Asia Pacific rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.9 Japan
                      6.9.1 Japan rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.10 China
                      6.10.1 China rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.11 Latin America
                      6.11.1 Latin America rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.12 Brazil
                      6.12.1 Brazil rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.13 Mexico
                      6.13.1 Mexico rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.14 MEA
                      6.14.1 MEA rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.15 South Africa
                      6.15.1 South Africa rare hemophilia factors market estimates and forecasts, 2014 - 2025
                 6.16 Saudi Arabia
                      6.16.1 Saudi Arabia rare hemophilia factors market estimates and forecasts, 2014 - 2025
Chapter 7 Competitive Landscape
                 7.1 Company Profiles
                      7.1.1 Novo Nordisk
                           7.1.1.1 Company overview
                           7.1.1.2 Financial performance
                           7.1.1.3 Product benchmarking
                           7.1.1.4 Strategic initiatives
                      7.1.2 Biogen
                           7.1.2.1 Company overview
                           7.1.2.2 Financial performance
                           7.1.2.3 Product benchmarking
                           7.1.2.4 Strategic initiatives
                      7.1.3 Bayer Healthcare
                           7.1.3.1 Company overview
                           7.1.3.2 Financial performance
                           7.1.3.3 Product benchmarking
                           7.1.3.4 Strategic initiatives
                      7.1.4 Pfizer, Inc.
                           7.1.4.1 Company overview
                           7.1.4.2 Financial performance
                           7.1.4.3 Product benchmarking
                           7.1.4.4 Strategic initiatives
                      7.1.5 Shire
                           7.1.5.1 Company overview
                           7.1.5.2 Financial performance
                           7.1.5.3 Product benchmarking
                           7.1.5.4 Strategic initiatives
                      7.1.6 Baxalta (Baxter Healthcare)
                           7.1.6.1 Company overview
                           7.1.6.2 Financial performance
                           7.1.6.3 Product benchmarking
                           7.1.6.4 Strategic initiatives
                      7.1.7 CSL Behring
                           7.1.7.1 Company overview
                           7.1.7.2 Financial performance
                           7.1.7.3 Product benchmarking
                           7.1.7.4 Strategic initiatives
                      7.1.8 Bio Products Laboratory Ltd.
                           7.1.8.1 Company overview
                           7.1.8.2 Product benchmarking

List of Tables

TABLE 1 Global rare hemophilia factors market estimates and forecast by region, 2014 - 2025 (USD Million) 
TABLE 2 Global rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 3 Global rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 8 North America rare hemophilia factors market estimates and forecast by country, 2014 - 2025 (USD Million) 
TABLE 9 North America rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 10 North America rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 14 U.S. rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 15 U.S. rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 20 Canada rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 21 Canada rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 26 Europe rare hemophilia factors market estimates and forecast by country, 2014-2025 (USD Million)
TABLE 27 Europe rare hemophilia factors ls market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 28 Europe rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 32 U.K. rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million)
TABLE 33 U.K. rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 38 Germany rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million)
TABLE 39 Germany rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 44 Asia Pacific rare hemophilia factors market estimates and forecast by country, 2014 - 2025 (USD Million) 
TABLE 45 Asia Pacific rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 46 Asia Pacific rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 50 China rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million)
TABLE 51 China rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 56 Japan rare hemophilia factor market estimates and forecast by type, 2014 - 2025 (USD Million)
TABLE 57 Japan rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 62 Latin America rare hemophilia factor market estimates and forecast by country, 2014-2025 (USD Million)
TABLE 63 Latin America rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 64 Latin America rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 68 Brazil rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 69 Brazil rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 74 Mexico rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million)
TABLE 75 Mexico rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 80 Middle East & Africa rare hemophilia factors market estimates and forecast by country, 2014 - 2025 (USD Million)
TABLE 81 Middle East & Africa rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 82 Middle East & Africa rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 86 South Africa rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million) 
TABLE 87 South Africa rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million) 
TABLE 92 Saudi Arabia rare hemophilia factors market estimates and forecast by type, 2014 - 2025 (USD Million)
TABLE 93 Saudi Arabia rare hemophilia factors market estimates and forecast by treatment, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary (Figures in USD Million, 2016)
FIG. 8 Market trends & outlook
FIG. 9 Rare Hemophilia Factors Market: Market Segmentation
FIG. 10 Rare hemophilia factors market revenue, 2014 - 2025 (USD Million)
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Market restraint relevance analysis (Current & future impact)
FIG. 13 Penetration & growth prospect mapping
FIG. 14 SWOT analysis, by factor (Political & Legal, Economic and Technological)
FIG. 15 Per capita healthcare spending, by country, 2016 (USD)
FIG. 16 Porter's Five Forces Analysis
FIG. 17 Key strategies adopted by market players, 2016
FIG. 18 Rare hemophilia factors market type outlook key takeaways
FIG. 19 Rare hemophilia factors market: Type movement analysis
FIG. 20 Factor I market, 2014 - 2025 (USD Million)
FIG. 21 Factor II market, 2014 - 2025 (USD Million)
FIG. 22 Factor V market, 2014 - 2025 (USD Million)
FIG. 23 Factor VII market, 2014 - 2025 (USD Million)
FIG. 24 Factor X market, 2014 - 2025 (USD Million)
FIG. 25 Factor XI market, 2014 - 2025 (USD Million)
FIG. 26 Factor XIII market, 2014 - 2025 (USD Million)
FIG. 27 Rare hemophilia factors market treatment outlook key takeaways
FIG. 28 Rare hemophilia factors market: Treatment movement analysis
FIG. 29 Factor concentrate market, 2014 - 2025 (USD Million)
FIG. 30 Fresh frozen plasma market, 2014 - 2025 (USD Million)
FIG. 31 Cryoprecipitate market, 2014 - 2025 (USD Million)
FIG. 32 Others market, 2014 - 2025 (USD Million)
FIG. 33 Regional market place: Key takeaways
FIG. 34 Regional outlook, 2016 & 2025
FIG. 35 North America rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 36 U.S. rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 37 Canada rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 38 Europe rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 39 U.K. rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 40 Germany rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 41 Asia Pacific rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 42 Japan rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 43 China rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 44 Latin America rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 45 Brazil rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 46 Mexico rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 47 MEA rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 48 South Africa rare hemophilia factors market, 2014 - 2025 (USD Million)
FIG. 49 Saudi Arabia rare hemophilia factors market, 2014 - 2025 (USD Million)